IVB105

IVB105 is an investigational AAV-based gene therapy being developed by InnoVec Biotherapeutics for the treatment of retinitis pigmentosa and associated vision loss. The therapy employs an optogenetic approach, utilizing an adeno-associated virus (AAV) vector to deliver the OPN3 (Opsin 3) gene directly to retinal cells. By expressing this light-sensitive protein, the therapy aims to restore visual function in patients where photoreceptor cells have degenerated by conferring light sensitivity to the remaining retinal architecture. IVB105 is administered via intravitreal injection and has received Rare Pediatric Disease Designation (RPD) from the U.S. FDA. It is currently in the IND-enabling stage of development.